Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Paul Knoebl

Professor

Medical University of Vienna

Austria

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Internal Medicine

60%

Pharmacotherapy

90%

Hemostasis

50%

Hemophilia

50%

Bleeding Disorders

50%

Antibody Therapy

40%

Renal Replacement Therapy

40%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles18

Development of a rapid and fully automated factor VIII inhibitor assay, insensitive to emicizumab, and a lowest level of quantification of 0.2 BU/mL

Article Link

Year:

2024

Management of Immune Thrombotic Thrombocytopenic Purpura without Therapeutic Plasma Exchange

Article Link

Year:

2024

Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura.

Article Link

Year:

2024

Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study

Article Link

Year:

2023

N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia.

Article Link

Year:

2023

Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group

Article Link

Year:

2023

Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study

Article Link

Year:

2023

Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study

Article Link

Year:

2023

100 Years of Thrombotic Thrombocytopenic Purpura: A Story of Death and Life

Article Link

Year:

2023

Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial

Article Link

Year:

2023

Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.

Article Link

Year:

2022

Long‐term follow‐up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post‐HERCULES study

Article Link

Year:

2022

Management of acquired hemophilia A in severe Covid-19: Hemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis.

Article Link

Year:

2022

Safer steps on a narrow path

Article Link

Year:

2022

Hereditary thrombotic thrombocytopenic purpura and COVID‐19: Impacts of vaccination and infection inrare disease

Article Link

Year:

2022

Successful treatment of vaccine‐induced prothrombotic immune thrombocytopenia (VIPIT)

Article Link

Year:

2021

Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura

Article Link

Year:

2021

Emicizumab for the treatment of acquired hemophilia A

Article Link

Year:

2021

Collaborators9

Wolfgang R. Sperr

AUSTRIA

Johanna A. Kremer Hovinga

SWITZERLAND

Katerina Pavenski

Head Division Transfusion Medicine

St. Michael's Hospital

CANADA

Evelyn Seelow

Charité - Universitätsmedizin Berlin

GERMANY

Ulf Schönermarck

GERMANY

Christian Pfrepper

GERMANY

Kathrin Eller

Assoc. Prof.

Medical University of Graz

AUSTRIA

Spero R. Cataland

Ohio State University

UNITED STATES

Adrian Schreiber

GERMANY

How do I reach out?

Meet Kite AI